CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

LUNG CANCER PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review, December 2014

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Combination therapy with α-galactosylceramide and a Toll-like receptor agonist exerts an augmented suppressive effect on lung tumor metastasis in a mouse model. Ando T, Ito H, Arioka Y, Ogiso H, Seishima M. Oncol Rep. 2014 Nov 28. doi: 10.3892/or.2014.3634. [Epub ahead of print]

A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. Vetsika EK1, Koinis F2, Gioulbasani M1, et al. J Immunol Res. 2014;2014:659294. doi: 10.1155/2014/659294. Epub 2014 Nov 11.

Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, et al. J Clin Invest. 2014 Dec 1;124(12):5466-5480. doi: 10.1172/JCI77053. Epub 2014 Nov 10.

Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells. Wang CK1, Zhang Y2, Zhang ZJ1, Qiu QW1, Cao JG3, He ZM1. Oncol Rep. 2015 Jan;33(1):372-82. doi: 10.3892/or.2014.3607. Epub 2014 Nov 13.

Loss of function of SWI/SNF chromatin remodeling genes leads to genome instability of human lung cancer. Huang HT, Chen SM, Pan LB, Yao J, Ma HT. Oncol Rep. 2015 Jan;33(1):283-91. doi: 10.3892/or.2014.3584. Epub 2014 Nov 3.

Racial diversity of actionable mutations in non-small cell lung cancer. Bollig-Fischer A1, Chen W, Gadgeel SM, Wenzlaff AS, Cote ML, Schwartz AG, Bepler G. J Thorac Oncol. 2014 Nov 7. [Epub ahead of print]

CYP2A6 Reduced Activity Gene Variants Confer Reduction in Lung Cancer Risk in African American Smokers – Findings from Two Independent Populations. Wassenaar CA1, Ye Y2, Cai Q3, et al. Carcinogenesis. 2014 Nov 21. pii: bgu235. [Epub ahead of print]

SCREENING, DIAGNOSIS AND STAGING

Efficient utilization of EBUS-TBNA samples for both diagnosis and molecular analyses. Oezkan F1, Khan A2, Zarogoulidis P3, et al. Onco Targets Ther. 2014 Nov 10;7:2061-2065. eCollection 2014.

Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination. Gierada DS1, Pinsky P2, Nath H2, Chiles C2, Duan F2, Aberle DR2. J Natl Cancer Inst. 2014 Oct 18;106(11). pii: dju284. doi: 10.1093/jnci/dju284. Print 2014 Nov.

Urinary protein biomarkers in the early detection of lung cancer. Nolen BM1, Lomakin A2, Marrangoni A3, Velikokhatnaya L3, Prosser D3, Lokshin AE4. Cancer Prev Res (Phila). 2014 Nov 21. pii: canprevres.0210.2014. [Epub ahead of print]

Point: Should Lung Cancer Screening by Chest CT be a Covered Benefit? Yes. Yankelevitz D. Chest. 2014 Nov 20. doi: 10.1378/chest.14-2812. [Epub ahead of print]

Prognostic and predictive markers for the new immunotherapies. Mahoney KM, Atkins MB. Oncology (Williston Park). 2014 Nov;28(11 Suppl 3). pii: 202335.

The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer. Rami-Porta R1, Bolejack V, Giroux DJ, et al. J Thorac Oncol. 2014 Nov;9(11):1618-1624.

Training in and Experience with Endobronchial Ultrasound. Bellinger CR1, Chatterjee AB, Adair N, Houle T, Khan I, Haponik E. Respiration. 2014 Nov 12. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – SURGERY

Racial Disparities in Operative Outcomes After Major Cancer Surgery in the United States. Sukumar S1, Ravi P, Sood A, et al. World J Surg. 2014 Nov 20. [Epub ahead of print]

The effect of gender on health-related quality of life and related factors in post-lobectomy lung-cancer patients. Chang NW1, Lin KC2, Hsu WH3, Lee SC4, Chan JY5, Wang KY6. Eur J Oncol Nurs. 2014 Nov 5. pii: S1462-3889(14)00178-1. doi: 10.1016/j.ejon.2014.10.015. [Epub ahead of print]

Initial experience of thoracoscopic lobectomy with partial removal of the superior vena cava for lung cancers. Xu X1, Chen H1, Yin W1, et al. Eur J Cardiothorac Surg. 2014 Nov 16. pii: ezu416. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – CHEMOTHERAPY

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. Zwitter M1, Stanic K2, Rajer M2, et al. Radiol Oncol. 2014 Nov 5;48(4):361-368. eCollection 2014.

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with non-adenocarcinoma non-small cell lung cancer. Scagliotti GV1, Bondarenko I2, Blackhall F3, et al. Ann Oncol. 2014 Nov 13. pii: mdu517. [Epub ahead of print]

 Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Doebele RC1, Spigel D, Tehfe M, et al. Cancer. 2014 Nov 6. doi: 10.1002/cncr.29132. [Epub ahead of print]

 PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non-Small-Cell Lung Cancer. Zinner RG1, Obasaju CK, Spigel DR, et al. J Thorac Oncol. 2014 Nov 26. [Epub ahead of print]

 Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. Yang ZY1, Liu L, Mao C, Wu XY, Huang YF, Hu XF, Tang JL. Cochrane Database Syst Rev. 2014 Nov 17;11:CD009948. doi: 10.1002/14651858.CD009948.pub2.

Extracellular Signal-Regulated Kinase 5 and Cyclic AMP Response Element Binding Protein Are Novel Pathways Inhibited by Vandetanib (ZD6474) and Doxorubicin in Mesotheliomas. Sayan M1, Shukla A, MacPherson MB, et al. Am J Respir Cell Mol Biol. 2014 Nov;51(5):595-603. doi: 10.1165/rcmb.2013-0373TR.

Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer. Lu B1, Sun L, Yan X, Ai Z, Xu J. Med Oncol. 2015 Jan;32(1):345. doi: 10.1007/s12032-014-0345-5. Epub 2014 Nov 28.

Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. Engle JA1, Kolesar JM2. Am J Health Syst Pharm. 2014 Nov 15;71(22):1933-1938.

The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC). Ding L1, Liu K, Jiang Z, Chen Q, Zhou N, Liang Y, Gao H, Hong X, Wu H. Tumour Biol. 2014 Nov 25. [Epub ahead of print]

Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non-Small-Cell Lung Cancer: An Analysis of Veterans Health Administration Data. Santana-Davila R1, Devisetty K2, Szabo A2, et al. J Clin Oncol. 2014 Nov 24. pii: JCO.2014.56.2587. [Epub ahead of print]

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-Small-Cell Lung Cancer. Blackhall F1, Kim DW, Besse B, et al. J Thorac Oncol. 2014 Nov;9(11):1625-1633.

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – RADIOTHERAPY

Evaluation of tumor localization in respiration motion-corrected cone-beam CT: Prospective study in lung. Dzyubak O1, Kincaid R1, Hertanto A1, et al. Med Phys. 2014 Oct;41(10):101918. doi: 10.1118/1.4896101.

Re-evaluation of the role of post-operative radiotherapy and the impact of radiation dose for non-small cell lung cancer using the National Cancer Database. Corso CD1, Rutter CE, Wilson LD, Kim AW, Decker RH, Husain ZA. J Thorac Oncol. 2014 Oct 16. [Epub ahead of print]

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. Sebastian M, Papachristofilou A, Weiss C, et al. BMC Cancer. 2014 Oct 6;14:748. doi: 10.1186/1471-2407-14-748.

Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.Bar-Ad V1, Leiby B, Witek M, et al. Am J Clin Oncol. 2014 Oct;37(5):433-7. doi: 10.1097/COC.0b013e31827de7a2.

Stereotactic body radiation therapy for stage I non-small cell lung cancer: a small academic hospital experience.Factor OB1, Vu CC2, Schneider JG3, et al. Front Oncol. 2014 Oct 20;4:287. doi: 10.3389/fonc.2014.00287. eCollection 2014.

Local Control and Toxicity in a Large Cohort of Central Lung Tumors Treated With Stereotactic Body Radiation Therapy. Modh A1, Rimner A1, Williams E2, et al. Int J Radiat Oncol Biol Phys. 2014 Oct 8. pii: S0360-3016(14)03657-8. doi: 10.1016/j.ijrobp.2014.08.008. [Epub ahead of print]

Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors following stereotactic radiation therapy for early-stage non-small cell lung cancer. Cannon NA1, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, Timmerman R. J Thorac Oncol. 2014 Oct 8. [Epub ahead of print]

SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. Maguire J1, Khan I2, McMenemin R3, O’Rourke N4, McNee S4, Kelly V5, Peedell C6, Snee M7. Eur J Cancer. 2014 Oct 7. pii: S0959-8049(14)00809-0. doi: 10.1016/j.ejca.2014.07.009. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – OTHER

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – SMALL CELL LUNG CANCER (SCLC)

Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study. Li C1, Xiong Y, Zhou Z, et al. Med Oncol. 2014 Dec;31(12):369. doi: 10.1007/s12032-014-0369-x. Epub 2014 Nov 22.

Early Growth Response 4 Is Involved in Cell Proliferation of Small Cell Lung Cancer through Transcriptional Activation of Its Downstream Genes. Matsuo T1, Dat le T2, Komatsu M1, et al. PLoS One. 2014 Nov 20;9(11):e113606. doi: 10.1371/journal.pone.0113606. eCollection 2014.

Association of GWAS-Identified Lung Cancer Susceptibility Loci with Survival Length in Patients with Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy. Li D1, Wei L2, Xu B3, et al. PLoS One. 2014 Nov 21;9(11):e113574. doi: 10.1371/journal.pone.0113574. eCollection 2014.

Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A. Pan B, Chen Y, Song H, Xu Y, Wang R, Chen L. Oncotarget. 2014 Nov 16. [Epub ahead of print]

Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. Ishii H1, Azuma K, Kawahara A, et al. J Thorac Oncol. 2014 Nov 6. [Epub ahead of print]

Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer. Go SI1, Kim RB, Song HN, et al. Med Oncol. 2014 Dec;31(12):323. doi: 10.1007/s12032-014-0323-y. Epub 2014 Nov 23.

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer. von Pawel J1, Jotte R2, Spigel DR2, et al. J Clin Oncol. 2014 Nov 10. pii: JCO.2013.54.5392. [Epub ahead of print]

Small cell lung cancer and progressive retinopathy. Morita M1, Fukuhara T1, Takahashi H2, Maemondo M1. BMJ Case Rep. 2014 Nov 24;2014. pii: bcr2014205888. doi: 10.1136/bcr-2014-205888.

Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers. Karve SJ, Price GL, Davis KL, Pohl GM, Smyth E, Bowman L. BMC Health Serv Res. 2014 Nov 13;14(1):555. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Pujol JL1, Paz-Ares L2, de Marinis F3, et al. Clin Lung Cancer. 2014 Nov;15(6):418-25. doi: 10.1016/j.cllc.2014.06.007. Epub 2014 Jun 21.

Supportive care needs and preferences of lung cancer patients: a semi-structured qualitative interview study. Brown NM1, Lui CW, Robinson PC, Boyle FM. Support Care Cancer. 2014 Nov 14. [Epub ahead of print]

Assessment and Management of Symptoms for Outpatients Newly Diagnosed With Lung Cancer. Reinke LF1, Feemster LC2, Backhus LM3, Gylys-Colwell I4, Au DH2. Am J Hosp Palliat Care. 2014 Nov 5. pii: 1049909114557635. [Epub ahead of print]

Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. Chacon-Cabrera A1, Fermoselle C, Urtreger AJ, et al. J Cell Physiol. 2014 Nov;229(11):1660-72. doi: 10.1002/jcp.24611.

COMPLEMENTARY & ALTERNATIVE THERAPY

Potent Anticancer Effects of Bioactive Mushroom Extracts (Phellinus linteus) on a Variety of Human Cancer Cells. Konno S, Chu K, Feuer N, Phillips J, Choudhury M. J Clin Med Res. 2015 Feb;7(2):76-82. Epub 2014 Nov 19.

Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer. Xue NZ1, Fang RM, Lin LZ. Chin J Integr Med. 2014 Dec;20(12):910-6. doi: 10.1007/s11655-014-2022-0. Epub 2014 Nov 27.

Bioassay-guided isolation and identification of bioactive compound from aerial parts of Luffa acutangula against lung cancer cell line NCI-H460. Vanajothi R1, Srinivasan P. J Recept Signal Transduct Res. 2014 Nov 12:1-8. [Epub ahead of print]

Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production. Kim A, Im M, Yim NH, Ma JY. Sci Rep. 2014 Nov 11;4:6994. doi: 10.1038/srep06994.

In Vitro α-Glucosidase Inhibition, Antioxidant, Anticancer, and Antimycobacterial Properties of Ethyl Acetate Extract of Aegle tamilnadensis Abdul Kader (Rutaceae) Leaf. R PC1, S NK, S M, S AK, B S DK. Appl Biochem Biotechnol. 2014 Nov 8. [Epub ahead of print]

MISCELLANEOUS WORKS

Effect of smoking on survival from non-small cell lung cancer: a retrospective Veterans’ Affairs Central Cancer Registry (VACCR) cohort analysis. Bhatt VR1, Batra R, Silberstein PT, Loberiza FR Jr, Ganti AK. Med Oncol. 2015 Jan;32(1):339. doi: 10.1007/s12032-014-0339-3. Epub 2014 Nov 28.

Lung Cancer Incidence Trends by Histology Type among Asian American, Native Hawaiian, and Pacific Islander Populations in the United States, 1990-2010. Cheng I1, Le GM2, Noone AM3, et al. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2250-65. doi: 10.1158/1055-9965.EPI-14-0493.

Impact of prior cancer on eligibility for lung cancer clinical trials. Gerber DE1, Laccetti AL2, Xuan L2, Halm EA2, Pruitt SL2. J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju302. doi: 10.1093/jnci/dju302. Print 2014 Nov.

Disparities in Treatment of Patients with Inoperable Stage I Non-Small Cell Lung Cancer: A Population-Based Analysis. Koshy M1, Malik R, Spiotto M, Mahmood U, Weichselbaum RR, Sher DJ. J Thorac Oncol. 2014 Nov 3. [Epub ahead of print]

Patients with multiple nodules and a dominant lung adenocarcinoma have similar outcomes and survival compared with patients who have a solitary adenocarcinoma† Castiglioni M1, Louie BE2, Wilshire CL3, Farivar AS3, Aye RW3, Gorden J3, Horton MP4, Vallières E3. Interact Cardiovasc Thorac Surg. 2014 Nov 6. pii: ivu366. [Epub ahead of print]

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. Yu HA1, Sima CS, Shen R, et al. J Thorac Oncol. 2014 Nov 20. [Epub ahead of print]

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers. Litvak AM1, Paik PK, Woo KM, Sima CS, Hellmann MD, Arcila ME, Ladanyi M, Rudin CM, Kris MG, Riely GJ. J Thorac Oncol. 2014 Nov;9(11):1669-1674.

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)